Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease - Full Text View

Purpose

This study is being conducted to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on cerebral spinal fluid Amyloid concentrations in healthy subjects and in subjects with mild cognitive impairment or early Alzheimer's disease.

Condition	Intervention	Phase
Mild Cognitive Impairment Alzheimer's Disease	Drug: EVP-0962 Drug: Placebo	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Amyloidosis

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Further study details as provided by FORUM Pharmaceuticals Inc:

Primary Outcome Measures:

The number of adverse experiences reported by subjects and/or observed by investigator and repeated clinical evaluations of physical examinations, vital signs, 12-lead ECG (electrocardiogram), and lab tests (hematology, chemistry, urinalysis) [ Time Frame: Screening (Day-45 to Day -1) through Day 23 (end of study visit) ]
To measure the rate of synthesis of Amyloid Beta in cerebral spinal fluid of healthy subjects [ Time Frame: 0-36 hours post dose ]
To measure the concentration of Amyloid Beta in cerebral spinal fluid [ Time Frame: 0-36 hours post dose ]

Secondary Outcome Measures:

To measure the rate of synthesis of Amyloid Beta and steady-state levels in the cerebral spinal fluid in MCI or early Alzheimer's disease patients [ Time Frame: 0-36 hours post dose ]
To determine single-and repeat-dose EVP-0962 pharmacokinetics in cerebral spinal fluid and plasma [ Time Frame: 0-36 hours post dose ]


Enrollment:	52
Study Start Date:	November 2012
Primary Completion Date:	October 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Arm 1 10 mg EVP-0962 Orally administered once daily for 14 days	Drug: EVP-0962 Arms: 1,2,3,4
Experimental: Arm 2 50 mg EVP-0962 Orally administered once daily for 14 days	Drug: EVP-0962 Arms: 1,2,3,4
Experimental: Arm 3 100 mg EVP-0962 Orally administered once daily for 14 days	Drug: EVP-0962 Arms: 1,2,3,4
Experimental: Arm 4 200 mg EVP-0962 Orally administered once daily for 14 days	Drug: EVP-0962 Arms: 1,2,3,4
Placebo Comparator: Arm 5 Placebo orally administered for 14 days	Drug: Placebo Arm 5

Detailed Description:

This is a randomized, double-blind, sequential escalating repeat daily dose study conducted in two parts. The first part is being conducted in healthy subjects and will evaluate safety, tolerability, and pharmacokinetics and pharmacodynamics of escalating EVP-0962 doses (10, 50 100 and 200 mg) or matching placebo following once-daily administration for 14 days. The second part will evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of EVP-0962 following once-daily administration for 14 days in patients with mild cognitive impairment or early Alzheimer's disease at the dose level selected based on the available safety, pharmacokinetics and pharmacodynamics observations in the first part.

Eligibility


Ages Eligible for Study:	45 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Part 1: Male and female subjects between the ages of 45 to 65 (inclusive) in good health with a BMI of 18-32 kg/m2 and negative urine drug screen of abuse test.
Part 2: Male and female subjects between the ages of 45 to 85 (inclusive), MRI/CT scans compatible with diagnosis of MCI or early AD, meets the classification of MCI due to AD as defined by the National Institute on Aging-Alzheimer's Association, and a BMI of 18-32 kg/m2(inclusive). Subjects must meet the following Cognitive criteria: Subject Memory Complaint, cognitive impairment in one or more areas, CDR-SB score less than or equal 1.0, MMSE greater than 24, and no impairment in social or occupational functioning.

Exclusion Criteria:

History of seizure disorder, symptomatic orthostatic hypotension, QTc values greater than 450 ms, positive drug screening tests
Pregnancy, nursing, (or if fertile female) not willing to utilize birth control measures during study
C-SSRS suicidal ideation score of 4 or 5
Unwilling to abstain from vigorous exercise
Concurrent disease other than MCI or early AD that is attributing to patient's cognitive impairment.
Lumbar spine X-rays show anatomic contraindications to lumbar puncture
History of spinal surgery or chronic low back pain
History of migraine headaches

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01661673

Locations


United States, California
Glendale Adventist Medical Center
Glendale, California, United States, 91206

Sponsors and Collaborators

FORUM Pharmaceuticals Inc

Parexel

More Information


Responsible Party:	FORUM Pharmaceuticals Inc
ClinicalTrials.gov Identifier:	NCT01661673 History of Changes
Other Study ID Numbers:	EVP-0962-002
Study First Received:	August 3, 2012
Last Updated:	January 10, 2014

Additional relevant MeSH terms:


Alzheimer Disease Cognition Disorders Mild Cognitive Impairment Dementia Brain Diseases Central Nervous System Diseases	Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

ClinicalTrials.gov processed this record on June 23, 2017